Search
Returning search results with filters:
Remove filter for
Category: Health products
Remove filter for
Last updated: 2020
Remove filter for
Type: Health professional risk communication
Clear all
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 15 of 28 items.
Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels
Authorization of Moderna COVID-19 Vaccine with English-only Vial and Carton Labels
Starting date:
December 23, 2020…
AlertHealth professional risk communication | 2020-12-23
Bacitracin for Injection (50,000 IU per vial) and the Risk of Nephrotoxicity and Anaphylactic Reactions
Bacitracin for Injection (50,000 IU per vial) and the Risk of Nephrotoxicity and Anaphylactic Reactions
Starting date:…
AlertHealth professional risk communication | 2020-12-21
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
Authorization of Bamlanivimab with English-only Labels for Use in Relation to the COVID-19 Pandemic
Starting date:…
AlertHealth professional risk communication | 2020-12-18
ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy
ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy
Starting date:
December 15, 2020…
AlertHealth professional risk communication | 2020-12-15
Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
Starting date:
December 12,…
AlertHealth professional risk communication | 2020-12-12
Importation of US-labelled Dexrazoxane for Injection distributed by Mylan Pharmaceuticals ULC due to shortage of Canadian-labelled Dexrazoxane
Importation of US-labelled Dexrazoxane for Injection distributed by Mylan Pharmaceuticals ULC due to shortage of Canadian-labelled Dexrazoxane…
AlertHealth professional risk communication | 2020-12-01
PICATO (ingenol mebutate gel, 0.015% and 0.05%) - Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer
PICATO (ingenol mebutate gel, 0.015% and 0.05%) - Product Withdrawal in Canada due to Potential Increased Risk of Skin Cancer…
AlertHealth professional risk communication | 2020-10-27
Benzocaine-Containing Products and the Risk of Methemoglobinemia in Children under Two Years of Age
Benzocaine-Containing Products and the Risk of Methemoglobinemia in Children under Two Years of Age
Starting date:…
AlertHealth professional risk communication | 2020-10-22
FIBRISTAL (ulipristal acetate tablets, 5 mg) - Voluntary Withdrawal in Canada due to Risk of Drug-Induced Liver Injury
FIBRISTAL (ulipristal acetate tablets, 5 mg) - Voluntary Withdrawal in Canada due to Risk of Drug-Induced Liver Injury…
AlertHealth professional risk communication | 2020-09-30
Importation of US Clinical Trial-Labelled Remdesivir for Injection Due to Shortage of Canadian-Labelled Remdesivir
Importation of US Clinical Trial-Labelled Remdesivir for Injection Due to Shortage of Canadian-Labelled Remdesivir
Starting…
AlertHealth professional risk communication | 2020-09-15
ESBRIET (pirfenidone) and the Risk of Drug-Induced Liver Injury
ESBRIET (pirfenidone) and the Risk of Drug-Induced Liver Injury
Starting date:
September 14, 2020
Posting date…
AlertHealth professional risk communication | 2020-09-14
Prescription Cough and Cold Products Containing Opioids and the Risk of Opioid Use Disorder in Children and Adolescents (< 18 years of age)
Prescription Cough and Cold Products Containing Opioids and the Risk of Opioid Use Disorder in Children and Adolescents (< 18 years of age…
AlertHealth professional risk communication | 2020-08-24
Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products
Methadone Treatment of Opioid Dependence and Potential Risk of Lack of Effect when Switching between Different Products…
AlertHealth professional risk communication | 2020-07-17
NARDIL (phenelzine sulfate) Shortage
NARDIL (phenelzine sulfate) Shortage
Starting date:
June 24, 2020
Posting date:
June 24, 2020…
AlertHealth professional risk communication | 2020-06-24
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke (including ischaemic and haemorrhagic stroke), and Glomerulonephritis…
AlertHealth professional risk communication | 2020-06-22